News | September 16, 2014

Tryton Medical Enrolls First U.S. Patient in the Extended Access Registry

Extended Access Registry designed to confirm results from Pivotal IDE Trial

Tryton Medical First U.S. Patient Extended Access Registry

September 16, 2014 — Tryton Medical Inc. announced that the first patient in the United States has been enrolled in the Extended Access Registry, a single arm study of its Tryton Side Branch Stent. The Tryton registry is designed to confirm the results from its Pivotal IDE Trial and is expected to enroll 133 patients from Europe and the United States. The first patient in the United States was enrolled by Jeffrey W. Moses, M.D., director cardiovascular interventions New York Presbyterian Hospital/Columbia University Medical Center & professor of medicine Columbia University College of Physician and Surgeons.

The Tryton Extended Access Registry builds on the results of the TRYTON IDE Study, which showed the benefit of the Tryton Side Branch Stent in a post-hoc analysis of the intended population, complex bifurcation lesions involving significant side branches. The Tryton Extended Access Registry is designed to confirm these findings. Results from this registry together with the results from the Pivotal IDE Trial will be submitted to the US Food and Drug Administration (FDA) for pre-market (PMA) approval.

“We are pleased to provide the U.S. ‘kick off’ case for the Tryon Extended Access Registry, which is now up and running in the U.S. and Europe. The case involved a complex LAD-Diagonal bifurcation, which went smoothly with a great angiographic result,” commented Jeffrey W. Moses, M.D., principal investigator at Columbia University. “This case underscores how Tryton brings predictability to the treatment of complex bifurcations. We look for this study to confirm results of the IDE trial, demonstrating utility of Tryton in the treatment of complex bifurcation lesions involving significant side branches."

“Tryton Medical is excited to reach this next milestone on our pathway to U.S. approval,“ said Shawn P. McCarthy, President & CEO of Tryton Medical. "We remain on track to be the first and only approved stent for coronary bifurcations in the U.S.”

The Tryton Side Branch Stent is commercially available in multiple countries within Europe, Middle East & Africa, is investigational in the United States, and is not available in Japan. Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions.

The Tryton Side Branch Stent System is built for bifurcation using proprietary Tri-Zone technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug eluting stent is then placed in the main vessel. The Tryton Side Branch Stent has now been used to treat more than 10,000 patients worldwide.

For more information: www.trytonmedical.com

Related Content

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp